Researchers highlighted the ubiquitin ligase KLHL6 as a lever for reversing CD8+ T-cell exhaustion and restoring antitumor immunity. The reported mechanism centers on KLHL6 targeting TOX and mitochondrial regulators, helping shift exhausted T cells toward a more functional state in preclinical settings. The work adds to the expanding immune-virology and exhaustion biology literature that increasingly treats exhaustion as a modifiable cellular program—one that can be therapeutically tuned alongside checkpoint inhibition.